retatrutide availability clinical trial UK: Progress, Expected Availability, and Safety Guidance (2026) Retatrutide Phase 3: TRIUMPH Program

Acute pancreatitis , whilst rare, represents a serious adverse effect associated with GLP-1 receptor agonists

Why real-world results sometimes lag behind trial data Trial participants receive regular monitoring, dietary counseling, and structured follow-up that promotes adherence and optimal behavior

For CY 2026, we are adjusting the CY 2025 ASC conversion factor ($54.895) by a wage index budget neutrality factor of 1.0000 in addition to the productivity-adjusted hospital market basket update of 2.6 percent, discussed previously, which results in a final CY 2026 ASC conversion factor of $56.322 for ASCs meeting quality reporting requirements

Genetic association of the catalase gene (CAT) with vitiligo susceptibility

Ultraviolet radiation can still damage DNA, accelerate photoaging, and increase skin-cancer risk

Trying to salvage a questionable vial is the definition of a false economy